Publications
Scientific publications, posters and presentations
View and download posters from recent key conferences
Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma
Inobrodib: A novel small molecule inhibitor of p300/CBP for the treatment of acute myeloid leukaemia and multiple myeloma
An open-label Phase I/IIa study to evaluate the safety and efficacy of Inobrodib, a first in clinic inhibitor of the p300/CBP bromodomains, as monotherapy in patients with advanced haematological malignancies
An open-label Phase I/IIa study to evaluate the safety and efficacy of Inobrodib as monotherapy and in combination in patients with advanced solid/metastatic tumours.
Inobrodib, a potent and selective p300/CBP bromodomain inhibitor, is targeted and differentiated from BET inhibitors in prostate cancer cell lines in vitro.
p300/CBP inhibitor CCS1477 targets 22Rv1 prostate tumour AR and c-Myc gene expression in vivo.
A first-in-class p300/CBP bromodomain inhibitor for the treatment of prostate cancer and hematologic malignancies.
Novel small molecule inhibitor of p300/CBP down-regulates androgen receptor (AR) and c-Myc for the treatment of prostate cancer and beyond
Therapeutic targeting of the p300/CBP bromodomain for the treatment of castration resistant prostate cancer (CRPC)
Targeting the bromodomain of p300/CBP for the treatment of castrate resistant prostate cancer
Characterisation of CCS1477: A novel small molecule inhibitor of p300/CBP for the treatment of CRPC
Latest press releases